Accession Number:

ADA361892

Title:

Training in support of research entitled "Development of PEA3 as a Potential Gene Therapy Agent for Breast Cancer".

Descriptive Note:

Annual rept. 1 Sep 97-31 Aug 98

Corporate Author:

M D ANDERSON CANCER CENTER HOUSTON TX

Personal Author(s):

Report Date:

1998-09-01

Pagination or Media Count:

45.0

Abstract:

Overexpression andor amplification of HER-2neu has been implicated in the genesis of a number of human cancers, especially breast and ovarian cancers. Transcriptional upregulation has been shown to contribute significantly to the overexpression of this gene. PEA3 is a DNA binding transcriptional factor and its consensus sequence exists on the HER-2neu promoter. We transfected PEA3 into the human breast and ovarian cancer cells that overexpress HER-2neu and showed that PEA3 dramatically represses HER-2neu transcription. and suppresses the oncogenic neu-mediated transformation in mouse fibroblasts. Expression of PEA3 selectively blocks the growth of human cancer cells that overexpress HER-2neu. Studies in the orthotopic ovarian cancer model demonstrated that expression of PEA3 preferentially inhibits growth and tumor development of human cancer cells that overexpress HER-2neu, through down regulation of HER-2neu-p185. Thus, PEA3 is a negative regulator of HER-2neu gene expression and functions as a tumor suppressor gene in the HER-2neu overexpressing human cancer cells.

Subject Categories:

  • Genetic Engineering and Molecular Biology
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE